S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ACHV · Achieve Life Sciences, Inc. Common Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Achieve Life Sciences Inc (ACHV)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$6.50
+0.02
(+0.31%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$6.50
$6.39
$6.66
52-WEEK RANGE
$6.50
$2.62
$8.64
What's happening
- ACHV is up 0.31% today, trading at $6.50. — Live quote
- Volume today (204,565) is well below its 3-month average of 1,758,070. (Finnhub fundamentals)
- Reports earnings on 2026-11-04, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.80 actual vs. $-0.16 estimated (-405.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 13
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ACHV
+28.37%
vs S&P 500
+16.44%
1-YEAR RETURN
ACHV
+107.14%
vs S&P 500
+91.61%
6-MONTH RETURN
ACHV
+76.73%
3-MONTH RETURN
ACHV
+1.75%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.80
Est. $-0.16
MISS -405.7%
2026-04-26 (Q1 2026)
$-0.19
Est. $-0.31
BEAT +39.6%
2026-01-26 (Q4 2025)
$-0.28
Est. $-0.28
MISS -1.1%
2025-10-26 (Q3 2025)
$-0.28
Est. $-0.26
MISS -6.7%
Valuation Measures & Ratios
Enterprise Value4$623.5M
Forward P/E5—
PEG Ratio6-0.73
Price / Sales (TTM1)36.84
Price / Book714.66
EV4 / Revenue34.99
EV4 / EBITDA—
Profit Margin-94.67%
Operating Margin-106.51%
Return on Equity (ROE8)-193.49%
Return on Assets (ROA9)-143.73%
Avg Volume (3M)1,758,070
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $610.8M | $157.3M | $162.7M | $77.5M | $92.9M |
| P/E | -5.45 | -3.14 | -3.10 | -1.67 | -2.31 |
| Price/Book | -41.62 | 14.73 | 4.84 | 1.86 | 9.04 |
| ROE | 763.80% | -469.69% | -156.17% | -111.64% | -392.00% |
| ROA | -58.86% | -151.50% | -100.88% | -78.93% | -147.28% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short17,474,108
Change from Prior Settlement+9.26%
% of Float—
Days to Cover (Short Ratio)10.88
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +107.1%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -1.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -94.7%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ACHV
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$74.8M | -$10.2M | -$14.4M | -$12.7M | -$12.8M | -$12.5M | -$8.5M | -$6.5M |
| EPS (diluted) | $-0.80 | $-0.19 | $-0.28 | $-0.37 | $-0.37 | $-0.36 | $-0.25 | $-0.26 |
| EPS (basic) | $-0.80 | $-0.19 | $-0.28 | $-0.37 | $-0.37 | $-0.36 | $-0.25 | $-0.26 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $190.4M | $33.1M | $41.8M | $52.0M | $58.9M | $27.4M | $38.6M | $47.9M |
| Total liabilities | $205.1M | $22.4M | $20.3M | $18.4M | $17.3M | $17.1M | $17.7M | $16.5M |
| Stockholders' equity | -$14.7M | $10.7M | $21.5M | $33.6M | $41.7M | $10.3M | $20.9M | $31.4M |
| Total current assets | $188.3M | $31.1M | $39.9M | $50.1M | $56.9M | $25.0M | $36.5M | $45.5M |
| Total current liabilities | $197.7M | $11.8M | $9.1M | $9.7M | $8.6M | $7.1M | $6.7M | $6.7M |
| Cash & equivalents | $48.0M | $28.1M | $20.9M | $31.9M | $51.9M | $13.0M | $12.8M | $9.5M |
| Marketable securities (current) | $139.3M | $1.2M | $15.5M | $16.2M | $3.5M | $10.2M | $21.6M | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | $3.0K | — | — | — | $8.0K | — |
| Goodwill | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Intangible assets | $640.0K | $696.0K | $751.0K | $807.0K | $863.0K | $918.0K | $974.0K | $1.0M |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | — | — | — | $1.9M | $1.2M | $1.7M | $1.9M | $1.0M |
| Accrued liabilities | $200.0K | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $170.0K | $121.0K | $121.0K | $121.0K | $118.0K | $103.0K | $103.0K | $103.0K |
| Retained earnings | -$345.2M | -$270.4M | -$260.2M | -$245.6M | -$231.1M | -$218.4M | -$205.6M | -$193.2M |
| Accumulated other comprehensive income (loss) | -$88.0K | $2.0K | $10.0K | $9.0K | $3.0K | $6.0K | $31.0K | $75.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$6.9M | -$18.0M | -$11.3M | -$9.1M | -$11.1M | -$9.2M | -$10.4M |
| Investing cash flow | -$137.8M | $14.3M | $709.0K | -$12.7M | $6.7M | $11.4M | $11.7M | $13.3M |
| Financing cash flow | $168.5M | $21.0K | $6.3M | $4.0M | $41.2M | — | $682.0K | -$8.1M |
| Free cash flow | -$10.8M | — | -$18.0M | — | — | — | — | — |
| Capital expenditures | $16.0K | — | $3.0K | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $7.0M | -$685.0K | $6.5M | $2.3M | $2.9M | $2.2M | $4.0M | $1.3M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Purchases of investments | $138.8M | $1.2M | — | $15.4M | $897.0K | $3.4M | — | $389.0K |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M |
| EPS (diluted) | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 |
| EPS (basic) | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M |
| Stockholders' equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M |
| Total current assets | $39.9M | $36.5M | $17.0M | $27.3M | $44.6M |
| Total current liabilities | $9.1M | $6.7M | $20.8M | $21.6M | $4.5M |
| Cash & equivalents | $20.9M | $12.8M | $15.5M | $24.8M | $43.0M |
| Marketable securities (current) | $15.5M | $21.6M | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $3.0K | $8.0K | $13.0K | $4.0K | $15.0K |
| Goodwill | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Intangible assets | $751.0K | $974.0K | $1.2M | $1.4M | $1.6M |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | — | $1.9M | $618.0K | $1.7M | $841.0K |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Common stock & paid-in capital | $121.0K | $103.0K | $90.0K | $87.0K | $79.0K |
| Retained earnings | -$260.2M | -$205.6M | -$165.8M | -$135.9M | -$93.6M |
| Accumulated other comprehensive income (loss) | $10.0K | $31.0K | $4.0K | $4.0K | $4.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M |
| Investing cash flow | $6.1M | -$21.6M | -$21.0K | — | — |
| Financing cash flow | $51.5M | $48.5M | $15.3M | $19.3M | $36.6M |
| Free cash flow | -$49.5M | — | -$24.5M | — | — |
| Capital expenditures | $3.0K | — | $21.0K | — | — |
| Share-based compensation | $8.8M | $5.3M | $3.4M | $3.3M | $2.2M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $114.0K | $220.0K | $47.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ACHV as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 33 filers
Held by These Filers182.7%
Shares Outstanding43,594,652
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | $49.7M | 17.47% | +0.0% | 2026-08-14 |
| TPG GP A, LLC | 6,877,580 | $44.9M | 15.78% | +0.0% | 2026-08-14 |
| venBio Partners LLC | 5,914,720 | $38.6M | 13.57% | +0.0% | 2026-08-14 |
| Logos Global Management LP | 5,425,000 | $35.4M | 12.44% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 5,272,017 | $34.4M | 12.09% | +1099.9% | 2026-08-07 |
| Franklin Resources Inc | 4,953,220 | $32.3M | 11.36% | +13.4% | 2026-08-04 |
| Paradigm Biocapital Advisors LP | 4,951,856 | $32.3M | 11.36% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,140,812 | $27.0M | 9.50% | +87.8% | 2026-06-30 |
| Propel Bio Management, LLC | 4,034,018 | $26.3M | 9.25% | +6.5% | 2026-08-13 |
| MARSHALL WACE, LLP | 3,770,313 | $24.6M | 8.65% | +269.9% | 2026-08-13 |
| State Street Corp | 2,945,526 | $19.2M | 6.76% | +1057.6% | 2026-08-07 |
| Vivo Capital, LLC | 2,751,032 | $18.0M | 6.31% | +0.0% | 2026-08-14 |
| Venrock Adviser, LLC | 2,751,032 | $18.0M | 6.31% | +0.0% | 2026-08-14 |
| Jupiter Topco LLC | 2,751,032 | $18.0M | 6.31% | +0.0% | 2026-08-14 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2,220,000 | $14.5M | 5.09% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,062,721 | $13.5M | 4.73% | +231.2% | 2026-08-12 |
| Alyeska Investment Group, L.P. | 1,925,722 | $12.6M | 4.42% | +0.0% | 2026-08-14 |
| Simplify Asset Management Inc. | 1,432,105 | $9.4M | 3.29% | +20.9% | 2026-07-16 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,426,915 | $9.3M | 3.27% | +0.0% | 2026-08-14 |
| LPL Financial LLC | 902,255 | $5.9M | 2.07% | +23.9% | 2026-08-07 |
| Northern Trust Corp | 743,760 | $4.9M | 1.71% | +230.9% | 2026-08-12 |
| Spruce Street Capital LP | 736,637 | $4.8M | 1.69% | +0.0% | 2026-08-13 |
| VANGUARD FIDUCIARY TRUST CO | 593,751 | $3.9M | 1.36% | +87.8% | 2026-06-30 |
| Raymond James Financial Inc | 546,318 | $3.6M | 1.25% | -14.9% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 537,596 | $3.5M | 1.23% | +0.0% | 2026-06-30 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-18 to 2026-08-19
Recent transactions
- Insiders have net sold 20,626 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Stewart Richard Alistair (Reporting person) — Open market sale of 20,626 shares on 2026-08-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)20,626 sh(1 txns)
Net Shares-20,626
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Stewart Richard Alistair | Reporting person | Open market sale | 2026-08-19 | 20,626 |
| Oki Mark K | Chief Financial Officer | Option exercise | 2025-09-18 | 168,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-19 | Stewart Richard Alistair | Reporting person | Open market sale | 20,626 | $8.49 |
| 2025-09-18 | Oki Mark K | Chief Financial Officer | Option exercise | 168,000 | $0.00 |
| 2025-09-18 | Oki Mark K | Chief Financial Officer | Open market sale | 50,060 | $2.92 |
| 2025-09-18 | Stewart Richard Alistair | Chief Executive Officer | Option exercise | 297,500 | $0.00 |
| 2025-09-18 | Stewart Richard Alistair | Chief Executive Officer | Open market sale | 129,501 | $2.92 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:27 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-01 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
Recent news
Headlines about ACHV (Achieve Life Sciences, Inc. Common Shares). Links open the publisher — we don’t host full articles.
-
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Yahoo Finance · 2026-10-21 -
ACHV270319C00002500 interactive stock chart | ACHV Mar 2027 2.500 call stock
Yahoo Finance Australia · 2026-10-20 -
Achieve Life Sciences (Nasdaq:ACHV) - Stock Analysis
Simply Wall Street · 2026-10-18 -
Technical Reactions to ACHV Trends in Macro Strategies
Stock Traders Daily · 2026-10-18 -
ACHV Nov 2026 12.500 put (ACHV261120P00012500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-17 -
Achieve Life Sciences (NASDAQ:ACHV) Stock Falls 6% - Should You Sell?
MarketBeat · 2026-10-16 -
Achieve Life Sciences, Inc. (ACHV) - What Are Investment Firms Saying About This Stock?
MarketBeat · 2026-10-16 -
Achieve Life Sciences (NASDAQ:ACHV) Share Price Breaks Above 200-Day Moving Average - Time to Sell?
MarketBeat · 2026-10-16
No headlines in this category right now — try “All”.